glp-1 obesity drug news today 2025-10-20 Study finds 40% of prescriptions go unfilled: Is cost curbing use of weight loss drugs? McKee's proposed FY2027 budget drops
Description
58 Lixisenatide (Lyxumia) is not available in the US, but was approved in the European Union in 2013
Common injection sites are the stomach, upper leg, or upper arm
In clinical trials of Tirzepatide, a dual-acting GLP-1 and GIP agonist currently prescribed for Type 2 diabetes, obese patients lost 21 percent body mass in 1.4 years, surpassing the 15 percent reduction seen with Semaglutide
Journal of Molecular Endocrinology
Pairing these with consistent water intake makes them significantly more effective for relieving constipation
An additional barrier is that plans that cover GLP-1s generally use some type of prior authorization process to limit patient access
